Review



novus biologicals nbp2 30169  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Novus Biologicals novus biologicals nbp2 30169
    Novus Biologicals Nbp2 30169, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/Human+Prostate+Tissue+MicroArray+(Cancer)/ppr0620221-104-26-26
    Average 90 stars, based on 23 article reviews
    novus biologicals nbp2 30169 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Positive Control:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Microarray:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Article Title: Fluid shear stress facilitates prostate cancer metastasis through Piezo1-Src-YAP axis.
    Article Snippet: .. Human prostate cancer tissue microarray (TMA) was purchased from Novus (NBP2-30169, Saint Charles, MO, USA). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Normal human tissue microarray , US Biolabs , FDA999-1. .. Prostate cancer microarray , Novus Biologicals , NBP2-30169. .. Breast cancer microarray , BioMAx , BR1005b.

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    other:

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis
    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Software:

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).

    Immunohistochemistry:

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).



    Similar Products

    90
    CapitalBio Corporation luxscan 10k-b microarray scanner
    Luxscan 10k B Microarray Scanner, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/luxscan+10+k+microarray+scanner/nct06133946-1-30-34
    Average 90 stars, based on 1 article reviews
    luxscan 10k-b microarray scanner - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Innopsys Inc the innoscan 300 microarray scanner
    The Innoscan 300 Microarray Scanner, supplied by Innopsys Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/innoscan+300+microarray+scanner/nct06243497-6-1-6
    Average 90 stars, based on 1 article reviews
    the innoscan 300 microarray scanner - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    99
    Olympus issue microarray scanner
    Issue Microarray Scanner, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/VS120+Virtual+Slide+Microscope+Virtual+Slide+Microscopy/pm42814517-283-18-22
    Average 99 stars, based on 1 article reviews
    issue microarray scanner - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    94
    Danaher Inc microarray scanner
    Microarray Scanner, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/GenePix+Microarray+Systems/pm42772593-192-17-19
    Average 94 stars, based on 1 article reviews
    microarray scanner - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc cytokine protein microarray analysis cytokine protein levels
    Cytokine Protein Microarray Analysis Cytokine Protein Levels, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/Mouse+Cytokine+Array+GS1000/pm42680000-156-0-11
    Average 94 stars, based on 1 article reviews
    cytokine protein microarray analysis cytokine protein levels - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc jo urn al pr e p roo f 12 apoptosis protein microarray analysis apoptosis signaling
    Jo Urn Al Pr E P Roo F 12 Apoptosis Protein Microarray Analysis Apoptosis Signaling, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/Mouse+Apoptosis+Signaling+Pathway+Array+C1/pm42680000-150-0-18
    Average 94 stars, based on 1 article reviews
    jo urn al pr e p roo f 12 apoptosis protein microarray analysis apoptosis signaling - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    SCIENION non contact inkjet microarray printer
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Non Contact Inkjet Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/sciFLEXARRAYER+S12/pmc13380757-243-19-23
    Average 95 stars, based on 1 article reviews
    non contact inkjet microarray printer - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    RayBiotech inc antibody microarrays
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Antibody Microarrays, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/Human+Immune+Response+Array+GS1/pm42565727-46-14-19
    Average 94 stars, based on 1 article reviews
    antibody microarrays - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    SCIENION non contact microarray spotter
    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen <t>microarray</t> technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).
    Non Contact Microarray Spotter, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microarrays/sciFLEXARRAYER+S3/pmc13388467-92-19-24
    Average 96 stars, based on 1 article reviews
    non contact microarray spotter - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Journal: iScience

    Article Title: A rapid point-of-care test for vancomycin monitoring at the clinical bedside

    doi: 10.1016/j.isci.2026.116064

    Figure Lengend Snippet: The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Article Snippet: Following polymerization, D4 assays were fabricated using non-contact inkjet printing methods as described elsewhere., VANC-BSA was printed using a non-contact inkjet microarray printer (Scienion, sciFLEXARRAYER Type S12).

    Techniques: Polymer, Labeling, Dissolution, Diffusion-based Assay, Fluorescence, Concentration Assay

    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen microarray technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen microarray technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Isolation, Magnetic Beads, Incubation, Microarray

    Selection and validation of candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B) Heatmap showing the relative abundance of selected candidate retinal antigens across AMD stages. Red indicates increased abundance and blue indicates decreased abundance. Candidate antigens selected for further validation are highlighted with red boxes. (C–H) Antigen microarray validation of serum and tear autoantibody reactivity against selected retinal antigens, including PSMD6, HSPA12A, PTGES3, ATP5A1, PFKM, and SDHB, in CTRL and AMD subgroups. Data are presented as mean ± SE. *p < 0.05.

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Selection and validation of candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B) Heatmap showing the relative abundance of selected candidate retinal antigens across AMD stages. Red indicates increased abundance and blue indicates decreased abundance. Candidate antigens selected for further validation are highlighted with red boxes. (C–H) Antigen microarray validation of serum and tear autoantibody reactivity against selected retinal antigens, including PSMD6, HSPA12A, PTGES3, ATP5A1, PFKM, and SDHB, in CTRL and AMD subgroups. Data are presented as mean ± SE. *p < 0.05.

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Selection, Biomarker Discovery, Microarray

    Validation and overlap analysis of selected candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B–G) A subset of candidate retinal antigen targets identified by serum autoantibody-based proteomic profiling, including FTH1, SAG, VIM, PRMT5, SEC22B, and HIST2H2AA3, was selected for further validation by antigen microarray analysis in serum and tear samples from CTRL and AMD subgroups. Data are presented as mean ± SE, with whiskers indicating 1.96 × SE.*p < 0.05. (H) Venn diagram showing the overlap among serum proteomics-positive results, serum autoantibody microarray-positive results, and tear autoantibody microarray-positive results. The antigen microarray analysis was performed as a targeted validation of selected MS-derived retinal antigen targets. Candidate antigens supported by multiple datasets are highlighted in red.

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Validation and overlap analysis of selected candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B–G) A subset of candidate retinal antigen targets identified by serum autoantibody-based proteomic profiling, including FTH1, SAG, VIM, PRMT5, SEC22B, and HIST2H2AA3, was selected for further validation by antigen microarray analysis in serum and tear samples from CTRL and AMD subgroups. Data are presented as mean ± SE, with whiskers indicating 1.96 × SE.*p < 0.05. (H) Venn diagram showing the overlap among serum proteomics-positive results, serum autoantibody microarray-positive results, and tear autoantibody microarray-positive results. The antigen microarray analysis was performed as a targeted validation of selected MS-derived retinal antigen targets. Candidate antigens supported by multiple datasets are highlighted in red.

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Biomarker Discovery, Microarray, Derivative Assay